Candid Therapeutics focuses on revolutionizing treatment paradigms for autoimmune diseases.

Candid Therapeutics

Ken Song

President and CEO

Arvind Kush

Chief Financial and Business Officer

Bernie Huyghe

Timothy Lu

CMO and Chief Scientific Officer

Investment Bank Funded Companies (Top 10K)

Redmile Group Portfolio Companies

West Coast Companies With Fewer Than 100 Employees (Top 10K)

United States Early Stage Companies With Fewer Than 1000 Employees (Top 10K)

Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.

Fairmount Funds Management

TCG Crossover

venBio Partners

Venrock Healthcare Capital Partners

Series A - Candid Therapeutics

San Diego

California

United States

North America

North American Startup Funding Weakened In Q3 As Largest Deal Took Longer To Close

The 10 Biggest Rounds Of September: Safe Superintelligence’s $1B Raise Reigns Supreme

The Week’s 10 Biggest Funding Rounds: Another Big Week For Biotech And AI

These antibodies are designed to redirect T-cells to eliminate autoreactive B-cells, aiming to provide effective treatment for autoimmune diseases by achieving deeper B-cell depletion.

A bispecific antibody targeting BCMA and CD3, designed to eliminate B-cells responsible for producing harmful autoantibodies in autoimmune diseases.

A bispecific antibody targeting BCMA and CD3, developed to eliminate B-cells responsible for harmful autoantibodies, with potential use in autoimmune diseases.

Pakistan

Asia

United Kingdom

Europe

Moldova

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 16, 2024 6:08 AM	f7c7c3b0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 16, 2024 6:08 AM	697a3f91
crunchbase trigger	general	Nov 25, 2024 9:09 AM	67094e92
crunchbase profile	general	Nov 25, 2024 12:38 PM	2a4bf460
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:21 PM	d092142d
peers	general	Oct 16, 2024 6:08 AM	a15c63ab
news basic	general	Oct 16, 2024 6:08 AM	eba64c0d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CAND

COM:CANDIDRX

Candid Therapeutics